
In a real-world study of 147 Hepatitis C virus genotype 5 (HCV-GT-5) patients in France, 98% achieved sustained virological response at 12 weeks (SVR12) following direct-acting antiviral (DAA) treatment with regimens such as sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. A 99% SVR12 was achieved on an intention-to-treat basis and 100% per protocol, with only three patients requiring additional treatment. These findings demonstrate the high efficacy of DAAs for HCV-GT-5, even in a real-world setting.
Like
Save
Share